Clinical Trial

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Study acronym: MCD-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.
Protocol Amendment History 2 changes
critical Recruitment resumed after suspension 2026-08-13
notable Sponsor changed: University of Virginia -> AdventHealth Translational Research Institute 2026-08-13
Trial Details
NCT Number NCT05478707
Lead Sponsor AdventHealth Translational Research Institute
Conditions Diabetes Mellitus, Type 1, Endothelial Dysfunction
Enrollment 47 participants
Start Date 2023-10-05
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-12